412 related articles for article (PubMed ID: 6692381)
1. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
Schilcher RB; Young JD; Leichman LP; Haas CD; Baker LH
Cancer Res; 1983 Aug; 43(8):3907-11. PubMed ID: 6683127
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical evaluation of diaziquone in childhood cancer.
Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR
Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of aziridinylbenzoquinone (NSC 182986).
Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia.
Schulman P; Davis R; Lee E; Ellerton J; Staszweski H
Cancer Treat Rep; 1987; 71(7-8):755-7. PubMed ID: 3607786
[TBL] [Abstract][Full Text] [Related]
8. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
Griffin JP; Newman RA; McCormack JJ; Krakoff IH
Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
10. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
Rubin J; van Hazel GA; Schutt AJ; Moertel CG; O'Connell MJ
Am J Clin Oncol; 1982 Oct; 5(5):539-40. PubMed ID: 7180832
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical evaluation of AZQ in metastatic breast cancer.
Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Rivera G; Evans WE; Dahl GV; Yee GC; Pratt CB
Cancer Res; 1980 Nov; 40(11):4250-3. PubMed ID: 6258775
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical evaluation of AZQ in colorectal cancer.
Bedikian AY; Stroehlein JR; Karlin DA; Korinek J; Bodey GP
Am J Clin Oncol; 1982 Oct; 5(5):535-7. PubMed ID: 7180831
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of aziridinylbenzoquinone in refractory lymphoma.
Case DC; Hayes DM
Cancer Treat Rep; 1983 Nov; 67(11):993-6. PubMed ID: 6357437
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of aziridinylbenzoquinone (NSC 192986) in patients with previously treated acute leukemia.
Van Echo DA; Schulman P; Budman DR; Ferrari A; Wiernik PH
Am J Clin Oncol; 1982 Aug; 5(4):405-10. PubMed ID: 7113963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
